Central to the proposed legislation is a reduction in the minimum period of regulatory protection for innovative medicines. The draft suggests a reduction from the existing 10 years to 8 years, but with provisions for extensions based on specific criteria. This shift aims to find a balance between incentivizing innovation and ensuring broader patient access. Pharmaceutical manufacture... https://wcss.com/transformational-legislative-changes-for-european-pharma-what-you-need-to-know/